title: Pre- and posttransplant monitoring of alloantibodies by complement-dependent cytotoxicity and luminex methodologies in liver transplantation.
abstract: BACKGROUND
  This study evaluated the influence of circulating anti-HLA antibodies on outcomes of 97 liver allografts from deceased donors.
  
  
  METHODS
  Human leukocyte antigen (HLA) antibody screening was performed by both complement-dependent cytotoxicity (CDC) and multiparameter Luminex microsphere-based assays (Luminex assay).
  
  
  RESULTS
  The agreements between T- and B- cell CDC and Luminex assays were 67% and 77% for pre- and posttransplant specimens, respectively. Graft dysfunction was not associated with either positive pretransplant CDC or Luminex panel-reactive antibody (PRA) values. Likewise, positive posttransplant T- or B- cell CDC PRA values were not associated with graft dysfunction. In contrast, posttransplant Luminex PRA values were significantly higher among patients with graft dysfunction compared with subjects with good outcomes (P = .017).
  
  
  CONCLUSIONS
  Posttransplant monitoring of HLA antibodies with Luminex methodology allowed identification of patients at high-risk for poor graft outcomes.
authors.affiliation: Laboratory of Transplantation Immunology, University of São Paulo Medical School, São Paulo, Brazil. frmonte@usp.br
authors.forename: F
authors.initials: F
authors.lastname: Monteiro
authors.forename: H
authors.initials: H
authors.lastname: Rodrigues
authors.forename: J
authors.initials: J
authors.lastname: Kalil
authors.forename: M C
authors.initials: MC
authors.lastname: Castro
authors.forename: N
authors.initials: N
authors.lastname: Panajotopoulos
authors.forename: M
authors.initials: M
authors.lastname: Paredes
authors.forename: P
authors.initials: P
authors.lastname: Massarolo
authors.forename: S
authors.initials: S
authors.lastname: Mies
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D003167:Complement Activation; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D005453:Fluorescence; D006084:Graft Rejection / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D016031:Liver Transplantation / Q000276:immunology*; D015166:Monitoring, Immunologic / Q000379:methods*; D011237:Predictive Value of Tests; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006680:HLA Antigens; D007518:Isoantibodies